Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 10, 2026

Subversive Capital files 'Ex-Elon' ETFs with the SEC that strip Tesla and SpaceX from the S&P 500 and Nasdaq-100

View original at finance.yahoo.com
Subversive Capital files 'Ex-Elon' ETFs with the SEC that strip Tesla and SpaceX from the S&P 500 and Nasdaq-100 If you're sickened at the thought of making the world's first trillionaire richer, a pair of proposed anti-Elon ETFs may pique your interest…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SpaceX's inclusion in the Nasdaq-100 could attract $4.3 billion from fund managers forced to add it to their Nasdaq-related portfolios

    60% confidence

  • 36% of Americans have a 'very unfavorable opinion' of Elon Musk

    60% confidence

  • Subversive Capital's ETFs aim to provide capital appreciation by buying a broad universe of large-capitalization U.S. equity securities while excluding securities of companies founded, controlled, or led by Elon Musk, or with which Musk is otherwise primarily associated

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Subversive Capital files 'Ex-Elon' ETFs with the SEC that strip Tesla and SpaceX from the S&P 500 and Nasdaq-100 — Source | Via News | ViaNews Market